stockrow
Friday 6 November 2026
Export TECH’s income statement to Excel — free account
Bio-Techne Corp
TECH Healthcare Biotechnology
Bio-Techne Corp’s revenue for fiscal 2026 (year ended June 2026) was $1.2 billion, roughly unchanged from fiscal 2025.
- Revenue
- +1.33%
- EPS
- +418.2%
- Free cash flow
- −6.83%
- Total debt
- −42.2%
Quarter to June 2026, against a year earlier
72.79
0.13
+0.18%
Follow TECH
Alert me
Bio-Techne Corp (TECH) EPS (diluted)
Bio-Techne Corp's EPS (diluted) for fiscal 2026 was $1.16, up 152.2% from $0.46 in fiscal 2025. Over the past ten years it has ranged from $0.46 (fiscal 2025) to $1.76 (fiscal 2023); the current reading is higher than 75% of that period. Bio-Techne Corp ranks 37th of 580 Biotechnology companies by EPS (diluted).
EPS (diluted), annual
Embed this chart
Annual newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| FY2026 | $1.16 | 152.17% |
| FY2025 | $0.46 | (56.19%) |
| FY2024 | $1.05 | (40.34%) |
| FY2023 | $1.76 | 6.18% |
| FY2022 | $1.66 | 91.07% |
| FY2021 | $0.87 | (40.38%) |
| FY2020 | $1.46 | 135.63% |
| FY2019 | $0.62 | (24.92%) |
| FY2018 | $0.82 | 59.71% |
| FY2017 | $0.52 | (26.43%) |
Quarterly newest first
| Period | EPS (diluted) | Change |
|---|---|---|
| Jun 2026 | $0.35 | 9.37% |
| Mar 2026 | $0.32 | 33.33% |
| Dec 2025 | $0.24 | 0.00% |
| Sep 2025 | $0.24 | — |
| 42 more quarters | Free account |
Against its own ten years
Low $0.46
High $1.76
Ten-year median
$0.85
Current reading's percentile
75
EPS (diluted) against peers
| Company | EPS (diluted) |
|---|---|
| TGTX TG Therapeutics, Inc. compare | $2.74 |
| TECH Bio-Techne Corp | $1.15 |
| CAI Caris Life Sciences,�Inc. compare | $0.33 |
| BMRN BioMarin Pharmaceutical Inc. compare | −$0.10 |
| IBRX ImmunityBio, Inc. compare | −$0.97 |
| SMMT Summit Therapeutics PLC compare | −$1.12 |
| TWST Twist Bioscience Corporation compare | −$2.22 |
| KYMR Kymera Therapeutics, Inc. compare | −$3.62 |
| PCVX Vaxcyte, Inc. compare | −$7.63 |
What EPS (diluted) is
Diluted EPS tells an investor how much profit a company earned for each share, counting the extra shares that options and convertible securities could create.
Reported line item
More on TECH
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement